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Abstract
Motivation: Reverse phase protein array (RPPA) is a powerful dot-blot technology that allows studying protein expression
levels as well as post-translational modifications in a large number of samples simultaneously. Yet, correct interpretation of
RPPA data has remained a major challenge for its broad-scale application and its translation into clinical research. Satisfying
quantification tools are available to assess a relative protein expression level from a serial dilution curve. However,
appropriate tools allowing the normalization of the data for external sources of variation are currently missing.
Results: Here we propose a new method, called NormaCurve, that allows simultaneous quantification and normalization of
RPPA data. For this, we modified the quantification method SuperCurve in order to include normalization for (i) background
fluorescence, (ii) variation in the total amount of spotted protein and (iii) spatial bias on the arrays. Using a spike-in design
with a purified protein, we test the capacity of different models to properly estimate normalized relative expression levels.
The best performing model, NormaCurve, takes into account a negative control array without primary antibody, an array
stained with a total protein stain and spatial covariates. We show that this normalization is reproducible and we discuss the
number of serial dilutions and the number of replicates that are required to obtain robust data. We thus provide a ready-to-
use method for reliable and reproducible normalization of RPPA data, which should facilitate the interpretation and the
development of this promising technology.
Availability: The raw data, the scripts and the NormaCurve package are available at the following web site: http://
microarrays.curie.fr.
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Introduction
The technology of Reverse phase protein arrays (RPPA) [1],
first described in 2001 [2], is a quantitative microformat dotblot
approach. It consists in depositing very small amounts of protein
extracts onto microscope slides covered with nitrocellulose. Each
spot contains 1 ng or less of material and one array can contain up
to five thousand spots. Each array is then labeled with an antibody
that specifically recognizes a protein of interest. Thus, RPPA is the
opposite of forward arrays, also termed antibody arrays [3], where
a large selection of antibodies is fixed on the arrays and incubated
with one protein extract per array. The advantages of RPPA,
compared to antibody arrays, are the small amounts of samples
that are required and the possibility to compare protein expression
among a large number of samples in the same experiment. As for
antibody arrays, the major constraint in RPPA lies in the quality of
the used primary antibodies, and systematic validation of their
specificity in Western Blot is required. Given the advantages of
RPPA, the technology has gained interest notably in the field of
cancer proteomics [4,5]. Examples of successful applications
include the identification of activated signaling pathways in
different types of cancer [6–8] and the identification of prognostic
biomarkers [9–11]. However, a major issue that is still under
development concerns the quantification and the normalization of
the data. Indeed, serial dilutions are generally made of each
sample, which allows appreciating the dynamic range of an
antibody. From these serial dilutions, one relative protein
expression level needs to be obtained for each sample for further
analysis. This step is termed the quantification of the data. Next,
the normalization of the data aims to correct for potential sources
of variability that do not reflect biological differences in protein
expression between the samples under investigation. These include
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deposited, (ii) differences in the fluorescence background inten-
sities and (iii) spatial effects on the slides.
Several quantification methods have been proposed. Some of
them use a sample-by-sample strategy [12,13] with linear or
logistic models. In this case, a curve is fitted to the serial dilutions
for each sample separately, and from this curve the final protein
expression level of the sample will be read. Next, these models
were improved by applying a joint strategy using all the samples of
the array to fit the curve [14]. The joint logistic strategy was shown
to improve the accuracy and the dynamic range of the estimated
protein expression levels over sample-by-sample estimations [14].
In addition, Hu et al. [15] showed that a non-parametric approach
is more flexible than the logistic model and may be applied to a
greater set of data. Their algorithm is applied array by array and it
is implemented in the SuperCurve R package [16]. Besides
SuperCurve, a mathematically simpler model, called SerialCurve,
was proposed by Zhang et al. [17]. Instead of modeling the
response curve of an antibody, this model characterizes the
relationship between signals in successive dilution steps.
SuperCurve and Serial Curve are currently the most efficient
quantification methods. However, they do not normalize the data,
i.e. they do not remove external sources of variability. Given the
high sensitivity (up to the attomol range) and the high precision of
RPPA (CV of v15%), such variations are expected to bias the
results [18,19]. Few publications propose normalization methods:
Neeley et al. [20] proposed a normalization step, to be applied after
SuperCurve, which mainly removes inter-array variability.
Another method, called microenvironment normalization, was
developed to remove spatial effects within an array and is applied
before SuperCurve algorithm [21]. Although very powerful, this
method requires many positive control spots and thus significantly
diminishes the number of samples that can be analyzed on one
array. In conclusion, no satisfying methods for intra-array
normalization of RPPA data are currently available.
Here, we propose models to simultaneously quantify and
normalize RPPAs. We chose to base our models on SuperCurve
quantification, rather than on SerialCurve, since non-parametric
models are more flexible and may in some cases better fit observed
RPPA data [15,16]. Four different normalization models were
tested. To validate our results, an experiment using a purified
protein (Chk2) was used. In this experiment, human samples,
mouse samples and known concentrations of Bovine Serum
Albumin (BSA) solutions are studied, with or without the addition
of exogenous Chk2. The ability of our models to remove spatial
effects and to correct for variations in the total amount of spotted
proteins is then investigated. All our results are validated by cross-
validation and show that the best performing model takes into
account three parameters for normalization: one negative control
slide, one slide with a total protein stain, and spatial covariates
within the array. This model, which we call NormaCurve, allows
robust and reproducible normalization of RPPA data.
Materials and Methods
Cell lines and Protein Extraction
Cell lines from ATCC have been used in our experiments: NIH-
3T3 (ATCC CRL-1658), MCF10A (ATCC CRL-10317), BT20
(ATCC HTB-19) and T47D (ATCC HTB-133) and Jurkat T
(ATCC TIB-152). Cell lines are grown in appropriate medium
supplemented with 1% penicillin/streptomycin (Invitrogen 15140-
122) and 10% foetal calf serum (Invitrogen 10500-064), except
when serum starvation is applied. For protein extraction, cells are
washed twice in PBS and harvested in hot Laemmli buffer (50 mM
Tris pH=6.8, 2% SDS, 5% glycerol, 2 mM DTT, 2.5 mM
EDTA, 2.5 mM EGTA, 1x HALT Phosphatase inhibitor (Perbio
78420), Protease inhibitor cocktail complete MINI EDTA-free
(Roche 1836170, 1 tablet/10 mL), 2 mM Na3VO4 and 10 mM
NaF). Extracts are boiled for 10 min at 100uC, passed through a
fine needle to reduce viscosity and centrifuged 10 min at
15000 rpm. The supernatant is harvested and stored at 280uC.
Protein concentration is determined (Pierce BCA reducing agent
compatible kit, ref 23252).
RPPA Experiment
Purified Chk2 protein (Abnova, H00011200-P01) is added to
cell extracts or to BSA (Sigma-Aldrich) solutions and detected
using a monoclonal antibody against Chk2 (Cell Signaling
Technology 3440). The following samples are deposited onto
nitrocellulose covered slides (Schott Nexterion NC-C) using a
dedicated arrayer (Aushon Biosystems 2470). The design is
summarized in the Table 1 and consists of the following extracts:
1. NIH-3T3 cells: the antibody against Chk2 does not recognize
the murine protein. Thus, total protein staining is expected to
be high while background levels are expected with the anti-
Chk2 antibody. The background level corresponds here to
non-specific binding and autofluorescence of the nitrocellulose.
2. NIH-3T3 cells + purified Chk2 protein: both total protein
staining and anti-Chk2 staining are expected.
3. BSA alone: total protein staining is expected to be high while
background levels are expected with the anti-Chk2 antibody.
4. BSA + purified Chk2 protein: both total protein staining and
anti-Chk2 staining are expected
5. MCF10A cells: both total protein staining and anti-Chk2
staining are expected,
6. MCF10A cells + purified Chk2 protein: both total protein
staining and anti-Chk2 staining are expected
7. Several control cell lines (BT20, jurkat, serum-starved
MCF10A, T47D)
For each sample, 15 2-fold serial dilutions are deposited, starting
at 1 mg/ml. For the extracts 1 to 4, starting concentrations of 0.8,
0.9, 1, 1.1 and 1.2 mg/ml were used, complemented or not with
respectively 0.033, 0.038, 0.042, 0.046 and 0.05 ng/ml purified
Chk2. The aim of these varying starting concentrations is to
introduce a variability in the spotted amount of total protein, in
order to test the ability of our models to correct for this. Samples
were divided over two 384-well plates. Each well contained
w20 ml of extract. In the first well plate, all wells were used and
the plate remained open for 125 minutes during printing. In the
second well plate, one fourth of the wells was used and the plate
remained open for 42 minutes. Total printing time was 3 h 48 min
and humidity was kept at w60% during the entire printing process
to avoid evaporation. All samples were deposited 6 times on each
array (technical replicates). A custom printing was used in order to
distribute samples as randomly as possible over the array.
Five arrays are stained with the total protein stain Sypro Ruby
(noted sypro). For this, arrays are incubated 15 min in 7% acetic
acid and 10% methanol, rinsed twice in water, incubated 10 min
in Sypro Ruby protein blot stain (S11791, Invitrogen) and rinsed
again.
In addition, five arrays are labeled with anti-Chk2 antibody
(CST 3440) and five arrays are labeled without primary antibody
(negative control, noted ctrl), using an Autostainer Plus (Dako).
Briefly, slides are incubated with avidin, biotin and peroxydase
blocking reagents (Dako) before saturation with TBS containing
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probed overnight at 4uC with primary antibodies (or without
primary antibody for negative controls) diluted in TBST-BSA.
After washes with TBST, arrays are probed with horseradish
peroxidase-coupled secondary antibodies (Jackson ImmunoRe-
search Laboratories) diluted in TBST-BSA for one hour at room
temperature. To amplify the signal, slides are incubated with Bio-
Rad Amplification Reagent for 15 minutes at room temperature.
The arrays are washed with TBST, probed with Cy5-Streptavidin
(Jackson ImmunoResearch Laboratories) diluted in TBST-BSA
for one hour at room temperature and washed again in TBST.
The processed slides are dried by centrifugation and scanned
using a GenePix 4000B microarray scanner (Molecular Devices).
Spot intensity was determined with MicroVigene software
(VigeneTech Inc).
SuperCurve Model and Extensions
Initial SuperCurve. Hu et al. [15] proposed a non-paramet-
ric model to quantify relative protein expression levels from RPPA
experiments. The model is yij ~f1(stepsi zexpLevelj)zEij
where yij is the intensity measured by the scanner at the ith
dilution step for the jth sample, stepsi is the dilution step,
expLevelj is the median effective relative protein expression level
(called EC50), f1 is a non-parametric monotonically increasing
function and Eij is the random error with a median assumed to be
0. The stepsi values are log-scaled dilution factors centered on
their median (i.e equal 22, 21, 0, 1 and 2 for the respective
dilution factors 1/16, 1/8, 1/4, 1/2 and 1). This model
corresponds to ModelSC11 of Table 2. In this model, the
function f1 and expLevelj are unknown but estimated using the
following iterative algorithm (see [15] for details):
1. for each sample j, the initial estimation of expLevelj is
computed using the following logistic function:
yij~azb|
expfc(stepsizexpLevelj)g
1zexpfc(stepsizexpLevelj)g
zEij ð1Þ
where a, b, c and expLevelj are unknown parameters.
2. from all the samples and based on the initial estimates of
expLevelj, the function f1 is estimated by a constrained quadratic
b-spline via the R package cobs.
3. conditionally on the estimated curve f1, the concentrations
expLevelj are estimated by a non-linear regression series by series.
A dilution series corresponds here to the intensities of a given
sample with all its dilution steps.
4. The steps 2 and 3 are iterated twice.
This algorithm is applied array by array and was implemented
in the R package SuperCurve [16]. While allowing the quanti-
fication of the relative protein expression levels expLevelj at the
step 0, SuperCurve does not take into account potential sources of
variability which may bias the measurements. Therefore, we
propose extented SuperCurve models in what follows in order to
improve the signal-to-noise ratio of the data.
Extended SuperCurve. Based on SuperCurve, we propose
models taking into account several covariates which can be
separated into two main groups. The first group of covariates
corresponds to features which depend on the experimental design.
They are the Sample effect which takes into account the
differences between the spotted samples, the covariates Row and
Col which take into account spatial effects on the array, the
Replicate covariate which takes into account the fact that a sample
is spotted in at least two replicates within an array. The covariates
expLevel and steps also fall into this group. The second group of
covariates corresponds to features which are not directly
quantified on the array of interest. They are the covariate ctrl
which corresponds to the intensities of the control array without
primary antibody and the covariate sypro which corresponds to
the intensities of the Sypro Ruby array. These covariates are used
to correct the background level and the total amount of spotted
proteins, respectively. We defined four models (ModelSC1 to
ModelSC4) depending on which covariates from the first group
are included (see Table 2). In addition, for each ModelSC, four
sub-models are tested depending on which covariates from the
second group are considered. The suffixes 1, c, s and cs are added
to the name of the model in order to distinguish the model with
neither ctrl nor sypro, with only ctrl, with only sypro and with the
ctrl and sypro, respectively. For instance, the test of the ModelSC2
with neither ctrl nor sypro will be noted ModelSC21 while the test
with both ctrl and sypro covariates will be noted ModelSC2cs. Five
ctrl slides and five sypro slides have been performed. From the 25
possible combinations of (ctrl, sypro), nine were tested here. These
nine combinations use each array twice.
For all models, a non-parametric function f1 assesses the
expLevel and step effects as in the initial SuperCurve model. For
ctrl and sypro, a linear relationship between the intensities of the
ctrl (or sypro) and the intensities of the specific antibody arrays
(here anti-Chk2 array) was tested and gave poor results (not
shown). Thus, non-parametric functions were used.
In order to add these covariates to the initial SuperCurve model
(ModelSC11), a generalized additive model (gam) of the R
package mgcv [22] was added. In a gam model, the linear predictor
is given by a user specified sum of smooth functions of the
covariates plus a conventional parametric component of the linear
predictor. The likelihood of gam models is modified by the
addition of one or more quadratic penalty coefficient matrices for
each smooth function. Each penalty matrix is multiplied by an
associated smoothing parameter assessed by the minimization of
the REML criterion. The penalities are chosen to minimize an
estimator of the resulting mean squared predictor error [22].
Contrarily to the cobs function, the gam function does not take
into account monotonicity contraints. Consequently, the use of
this function induces the loss of monotonicity in the curve estimate.
The model fitting is performed in the same way as in the initial
SuperCurve algorithm except the second step which is modified as
follows. Based on the initial estimates of expLevelj, all the
Table 1. ModelSC 1: Capacity of the different models to
normalize for the varying amounts of total protein spotted.
Array Sample pvalØ pvals pvalc pvalcs
1 BSA 3.5969e-05 0.1449 0.0420 0.3053
2 BSA 8.2330e-06 0.0991 0.0802 0.2175
3 BSA 1.5165e-06 0.5173 0.0003 0.0063
4 BSA 3.9442e-04 0.3741 0.0016 0.2308
5 BSA 8.2330e-06 0.0991 0.0802 0.2175
1 3T3 3.3674e-08 0.0710 0.0616 0.0644
2 3T3 1.0865e-06 0.2752 0.0561 0.0536
3 3T3 2.1981e-07 0.1603 0.6549 0.2578
4 3T3 1.6289e-10 0.2555 0.1080 0.2672
5 3T3 1.0865e-06 0.2752 0.0561 0.0536
Represented are the p-values of the amount effects without neither ctrl nor
sypro (pval1), with ctrl (pvalc), with sypro (pvals), with ctrl and sypro (pvalcs).
doi:10.1371/journal.pone.0038686.t001
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terms) are estimated by a gam model via the R package mgcv.
In ModelSC4, as the Replicate effect is considered as a random
effect, the third step of the algorithm detailed above has been
modified to assess relative protein expression levels from all the
series of a sample instead of series by series like in the other
models.
The SuperCurve models of Table 2 are applied array by array
and was implemented into the initial SuperCurve package.
Validation Criteria
In order to compare the different models, we defined three criteria:
a cross-validation criterion, a regression criterion and the correlation
coefficient. The cross-validation (CV) criterion establishes a model
using a training set, which is then validated on a separate set of
samples in order to control the robustness and the generalization of a
model. The regression criterion reflects how representative the fitted
curve is for the real data. The correlation coefficient corresponds to
the correlation between the true protein concentrations and the
relative expression levels estimated by the model.
1. Cross-validation (CV) criterion. For the samples NIH-
3T3, BSA and MCF10A, the concentrations of Chk2 are known
(either absolutely or up to a delta as there is an unknown base level
expression of Chk2). From these samples, both a training set and a
test set were built (this procedure is repeated 30 times). Without
loss of generality, let us consider the ModelSC1cs. On a given
training set and test set, a 5-fold CV criterion is computed as
follows:
- On the training set (4/5 of the data): estimates of the
parameters of the non-parametric functions ^ f fi and of the other
covariates,
- On the test set (1/5 of the data):
* Estimate of
yij{^ f f2(ctrlij){^ f f3(syproij)~^ f f1(stepsizexpLevelj),
* From the true concentrations expLevelT,
^ f f1(stepsizexpLevelT) is computed,
* The cross-validation criterion is then:
Cr~
1
N
|
X
i,j
f^ f f1(stepsizexpLevelj)
{^ f f1(stepsizexpLevelT)g
2
ð2Þ
where corresponds to the total number of spots. This criterion is
the most important because it reflects the generalization and the
robustness of the model.
2. Regression criterion. Corresponds to the REML
coefficients of the gam function. We remind that the gam
smoothing regression uses a penalization parameter to avoid
overfitting.
3. Correlation coefficient. Corresponds to the correlation
coefficient between the true concentrations and the relative
expression level estimated by the ModelSC in the training set.
Normalization of the Total Amount of Spotted Proteins
As mentioned previously, small variations in the concentrations
of total protein are voluntarily introduced in order to assess the
ability of our models to correct for these differences. The two
samples NIH-3T3 and BSA are thus spotted starting from five
varying amounts : 0.8 mg/ml, 0.9 mg/ml, 1.0 mg/ml, 1.1 mg/ml
and 1.2 mg/ml. Each starting concentration is then serially diluted
2-fold to obtain 15 dilution steps. The following two step
procedure was then used:
1. First, the observed intensities (y) were normalized according
to the two control arrays (ctrl and sypro) given the normalized
intensities yNorm. Four cases can then be distinguished whatever
the ModelSC of Table 2: models without covariate (Equation 3),
with only ctrl (Equation 4), with only sypro (Equation 5) and with
the two covariates (Equation 6).
yNorm~y ð3Þ
yNorm~y{^ f f2(ctrl) ð4Þ
yNorm~y{^ f f3(sypro) ð5Þ
yNorm~y{^ f f3(sypro){^ f f2(ctrl) ð6Þ
2. The significance of the effect of the five amounts l (0.8, 0.9,
1.0, 1.1, 1.2 mg/ml) is tested on the samples BSA and NIH-3T3
via the following linear model 7 where stepsk corresponds to the
dilution step, amountl corresponds to the amount effect and
Table 2. The initial SuperCurve model (ModelSC11) and the extended SuperCurve models.
Name cs c s
ModelSC1 yij~f1(stepsizexpLevelj)zEij zf2(ctrlij) zf3(syproij) zf2(ctrlij)zf3(syproij)
ModelSC2 yijk~f1(stepsizexpLevelj)zz f2(ctrlij) zf3(syproij) zf2(ctrlij)zf3(syproij)
SamplekzEijk
ModelSC3 yijklm~f1(stepsizexpLevelj)zz f2(ctrlij) zf3(syproij) zf2(ctrlij)zf3(syproij)
SamplekzCollzRowmzEijklm
ModelSC4 yijkn~f1(stepsizexpLevelj)z
SamplekzReplicatenzEijkn
zf2(ctrlij) zf3(syproij) zf2(ctrlij)zf3(syproij)
SamplekzReplicatenzEijkn
The best model we propose is bolded.
doi:10.1371/journal.pone.0038686.t002
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effects, m is the sample and Eklm the normal residuals:
log(yNormklm)~mzstepskzamountl
z(steps,amount)klzEklm
ð7Þ
Spatial Effect Evaluation
To check if our normalization ModelSC removes spatial effects,
the significance of the two effects, Row and Col, was tested before
normalization on the observed intensities (yijk) and after normal-
ization on the estimated residuals (~ y yijk) of the ModelSC of Table 2.
This test was performed on any ModelSC, even if they do not
contain the spatial covariates Row and Col (ModelSC3) in order
to check if the other tested covariates (negative control and total
protein stain) can remove spatial effects or not. Equation 8 is the
linear model taking into account the effect of the jth row and of
the kth column for the ith sample. The significance of the
covariates Row and Col is tested by Fisher tests.
Valijk~mzRowjzColkzEijk ð8Þ
where
Valijk~
yijk if initial model
~ y yijk otherwise
(
Required Number of Replicates
We addressed how many technical replicates are required to
evidence a significant difference between two samples S1 and S2.
Each sample is composed of n replicates. We want to know the
minimum difference between the mean relative protein expression
of two samples (D~MeanexpLevel(S1){MeanexpLevel(S2)) required to
be significant. This test can be written as follows: H0 : D~0
against the hypothesis H1 : D=0. Two parameters may vary: n
the number of replicates within each sample and D the difference
between the two mean expression levels after applying Super-
Curve. By varying these two parameters, the power of the test can
be calculated. The power corresponds to the probability of
rejecting the null hypothesis H0 while H1 is true.
To performsuch a poweranalysis,the estimationof the intra-array
variability is required. Indeed, the higher the intra-array variability is,
the higher the mean difference D must be in order to have a relevant
power (a relevant power is usually fixed from 80%). The intra-array
variability (i.e the variance of the residuals Eijk) is assessed by the linear
mixed-effect model 9 [23] taking into account the sample fixed-effect
(Samplei)and the array random-effect (Arrayk)w h o s ev a r i a n c es2
array
corresponds to the inter-array variability.
expLevelijk~mzSampleizArraykzEijk ð9Þ
Results
We aim to present and validate new models allowing
normalization of RPPA data for possible sources of variability
that do not represent differences in the expression levels of the
protein of interest. These include fluorescence background signal,
differences in the total amount of deposited protein and spatial
bias on the arrays. All statistical models were described in the
Material and Method section.
In order to design an RPPA experiment with known concen-
trations of protein, we used purified Chk2 protein. Chk2 is a
medium-sized protein (around 60 kDa) involved in cell cycle arrest
and DNA damage response. Our antibody against Chk2 proved
highly specific in western blot analysis on human samples and does
not recognize the murine protein (Figure 1). Thus, exogenous
human Chk2 can be added to mouse cell extracts (NIH-3T3)
resulting in known Chk2 protein concentrations, within the
physiological context of a cell lysate. In addition, we added
recombinant Chk2 to human cell extracts (MCF10A) and to
solutions of Bovine Serum Albumin (BSA). We choose not to
deposit the recombinant protein alone, since this does not
represent a normal situation of antibody binding and detection.
The design of the RPPA arrays is detailed in the Materials and
Methods.
Three different stainings were applied: five arrays were labeled
with anti-Chk2 antibody, five arrays were labeled without primary
antibody (negative control, noted ctrl), and five arrays were stained
with the total protein stain Sypro Ruby (noted sypro). None of the
slides showed visible spatial bias and the negative control slides
showed low background levels (Figure 2A). Relative intensities of
each spot were determined using MicroVigene software (Figure 2B)
and quality control of the raw data was performed. Boxplots,
representing the raw intensities of 6 technical replicates for each
dilution step, demonstrate that replicates are highly reproducible
(Figure 2C; please note the scaling differences). To further
demonstrate the reproducibility of our replicates, we calculated
the coefficient of variation (CV, defined as (Standard Deviation/
Mean Intensity) 6100) for each sample and each dilution step, on
each array (Figure 2C). Median CV of all arrays, samples and
dilutions steps was 13.40%. However, we noticed that low
intensities are associated with high CVs and vice versa (Figure
S1). Indeed, median CV for samples with near-background
intensities (v1000) was 16.5%, while median CV for samples
with intermediate intensities (between 1000 and 10,000) was 9.6%,
and median CV for samples with high intensities (w10,000) was
3.9%. Observing high CVs on low intensities is not surprising,
since small variations on very low intensities give rise to high CVs.
For example, a sample for which the intensity of the replicates
ranged from 32 to 102, the mean intensity was 66.1 and the CV
42.6%. Since these values remain within the background noise, a
high CV for low intensities is not problematic. In addition, we
ensured that good correlations exist between the 5 replicate slides.
Indeed, mean Pearsons correlation coefficient was 0.98 for Chk2-
labeled slides, 0.72 for negative control slides and 0.99 for Sypro
Ruby stained slides. In conclusion, the quality of our raw data is
satisfactory in all aspects and we can thus pursue with data
analysis.
To start with, we compared parametric and non-parametric
models to analyze these data. In agreement with Hu et al., 2007,
we observe that non-parametric data better fit the data, in
particular for the negative control slide (not shown). We therefore
chose the non-parametric model SuperCurve as the basis for our
development. The different normalization models that we
developed, presented in the Material and Methods, have been
applied on these raw data. The evaluation of the normalization
described below (cross-validation estimation of relative protein
levels, spatial effect and correction for total amount of protein and
for spatial effects) uses only one set of ctrl and sypro arrays. The
Quantification and Normalization of RPPA Data
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arrays is studied afterwards.
Estimation of Relative Protein Expression Levels
We use three validation criteria (cross-validation, regression and
correlation criteria), described in the Material and Methods, to
assess how well the different normalization models (Table 2)
predict protein expression levels. The cross-validation (CV)
criterion establishes a model using a subset of the samples, called
the training set, and is then validated on a separate set of samples
in order to control the robustness and the generalization of a
model. The regression criterion reflects how representative the
fitted curve is for the real data. The correlation coefficient
corresponds to the correlation between the true protein concen-
trations and the relative expression levels estimated by the model.
Better prediction of the protein expression levels result in a lower
cross-validation criterion, a lower regression criterion and a higher
correlation coefficient.
The results of the three validation criteria is shown in Figure 3.
The ModelSC11 corresponds to the initial SuperCurve and is
used as a reference (its criterion value is set at 0). Our models,
including a negative control array (ModelSC1c), a sypro ruby
array (ModelSC1s) or both (ModelSC1cs), are compared to the
initial SuperCurve model. The addition of one covariate (either
ctrl or sypro) significantly improves the CV and regression criteria
(but not the correlation coefficient) compared to the initial
SuperCurve (pv0.05). The results were validated by unilateral
t-tests. Importantly, adding the two covariates (ctrl and sypro) even
further improves the normalization, since all three criteria are
significantly improved. Thus, the simultaneous quantification and
normalization with the two covariates ctrl and sypro improves the
robustness of the estimated protein expression levels. These results
still hold if we consider ModelSC2, ModelSC3 and ModelSC4.
Figure 3 summarizes the results obtained for the five anti-Chk2
arrays. The details of the criteria, array by array, can be found in
Figure S2.
Next, we compared the four models ModelSC1cs,2 cs,3 cs and
4cs, which all take into account a negative control array and a
sypro ruby array, but differ in the effects that are taken into
account (see Table 2). A summary of the results for the five anti-
Chk2 arrays is given in the Figure 4 and validated by bilateral t-
tests (the detailed array by array plots can be found in Figure S3).
Figure 4 shows that the regression criterion is significantly lower in
the model with the maximum of covariates (ModelSC3cs).
However, this result is not confirmed by the CV criterion or by
the correlation coefficient, which are not significantly different
across the four tested ModelSC. Thus, we conclude that, for the
prediction of protein expression levels, the different models
perform similarly, as long as they include both a ctrl and sypro
array for normalization.
Correction of the Total Amount of Spotted Proteins
The correction of RPPA data for the total amount of spotted
protein is a crucial issue. Indeed, variations in total amounts of
spotted protein are likely to happen involuntary in RPPA, mainly
due to imprecise protein dosage methods. Without normalization,
proteins could be erroneously considered as differentially ex-
pressed. In order to test the ability of our normalization models to
correct for differences in the total amount of spotted protein, some
samples were voluntarily spotted at varying amounts (0.8, 0.9, 1,
1.1 and 1.2 mg/ml starting concentrations). As expected, the
sypro arrays permit to distinguish the total amounts of spotted
Figure 1. Western Blot. Western Blot analysis of Chk2 protein levels on a panel of different cell lines shows a single band at the expected size and
no signal in the mouse cell line NIH-3T3. Molecular weights (kD) are indicated next to the protein ladder (first lane). FCS: Fetal Calf serum, Ir: irradiated.
doi:10.1371/journal.pone.0038686.g001
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this effect. Interestingly, ctrl arrays also reflect the spotted amounts
(Figure S5 ). These arrays may therefore also be useful to
normalize for variations in amounts of total protein.
Table 3 shows the p-values of the effect of the spotted amounts
(0.8, 0.9, 1, 1.1 and 1.2 mg/ml), using the linear model 7 (see
Material and Methods) applied on the ModelSC11, the
ModelSC1c, the ModelSC1s, the ModelSC1cs. As expected, the
ModelSC11 (i.e the initial SuperCurve model, without normali-
zation) is not able to correct for the varying amounts: it estimates
relative protein expression levels that are significantly different
between the varying spotted amounts. This observation demon-
strates the sensitivity of the RPPA technology and emphasizes the
need for a normalization step. Indeed, such variations of 20%
above or below the intended protein concentration are very likely
to occur in RPPA. We here show that, without normalization,
such variations significantly affect the estimated protein expression
levels. Applying a model taking into account at least one covariate
(ctrl and/or sypro) significantly improves the correction for the
spotted amounts. In most cases, the p-value is no longer
significant, indicating that the expression levels are considered
similar after normalization. Similar results are obtained with the
other ModelSC of Table 2.
In conclusion, the addition of at least one covariate (ctrl and/or
sypro) significantly corrects the bias that could be induced by
variations in the spotted amounts of total protein.
Figure 2. Quality control of raw RPPA data. A. Representative images of the Sypro Ruby labeled slides (left), the negative control slides (middle)
and the anti-Chk2 labeled slides (right). No spatial bias was detected visually. On each array, two identical blocks (superarrays) have been printed. The
upper block of 40640 dots is thus a replicate of the lower block. Within each block, samples are deposited in three replicates. Thus, in total, there are
6 replicates per array. B. Dot detection and quantification using MicroVigene software allows to convert images into quantitative numbers and gives
rise to raw data. C. Raw data obtained on a representative Chk2-labeled array are plotted against the 15 serial dilutions for the indicated samples.
Dilutions (dil) are centered around 0 and indicated below each graph. Mean, standard deviation (sd) and the coefficient of variation (cv) are indicated
for each dilution below each graph. Please note the differences in scaling between the four graphs.
doi:10.1371/journal.pone.0038686.g002
Figure 3. Prediction of protein expression: the benefit of using negative control and sypro ruby arrays. Summary of the three
evaluation criteria (CV criterion, regression criterion and correlation coefficient) of the ModelSC1 for the five anti-chk2 arrays. No: No normalization
(initial SuperCurve); Ctrl: addition of a negative control array; Sypro: addition of a total protein stained array; SyproCtrl: addition of both arrays. The
initial SuperCurve (ModelSC11) is used as a reference and set at 0 and the differences to this reference are computed for the other ModelSC1.
doi:10.1371/journal.pone.0038686.g003
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Spatial bias are often found in micro-array technologies. They
may be due to heterogeneous arrays or heterogeneous staining.
Although the samples are spotted in a random manner onto the
arrays, these spatial effects may lead to higher or lower signal in
some rows and/or columns and thus bias the results. In this
section, we will test if spatial effects are significantly present on raw
data. Then, we test if the ModelSC of Table 2 are able to remove
these effects.
For each ModelSC of Table 2, the significance of the effects
Row and Col is studied via the Equation 8 in the Materials and
Methods. By eye, we did not detect any spatial bias on the arrays.
Yet, we detect for each array at least one significant spatial effect
(Row and/or Col with pv0.05) on the raw data. Only the
ModelSC3, which takes into account the effects Row and Col
allows the total and reproducible removal of the spatial bias. For
the ModelSC 1, 2 and 4, no trend can be found.
From the previous results, we can conclude that the best model
is the ModelSC3cs, called NormaCurve from now on, which takes
into account the ctrl and sypro arrays for normalization and the
covariates Row and Col for correction of spatial bias.
Reproducibility of Control Arrays
It has been shown that inter-RPPA comparison is challenging in
RPPA due to high variability between slides [20]. Using a linear
mixed-effect model (detailed in Methods S1), we indeed observe a
significant difference in the raw data among the five replicate slides
of Chk2, ctrl and sypro.
All results described before are performed with one ctrl array
and one sypro array. Given the high inter-array variability, we
hypothesized that using different ctrl and/or sypro arrays may lead
to different results. Thus, all tests described above were
reproduced with other combinations of ctrl and sypro arrays.
Despite the high inter-array variability, a very good reproducibility
of the results is obtained, since we confirm with all combinations of
ctrl and sypro arrays that:
N Normalization with the two covariates ctrl and sypro improves
the robustness of the estimated protein expression levels
N Only ModelSC3 completely removes the spatial effects.
N The addition of at least one covariate (ctrl and/or sypro)
always leads to an improved normalization of the spotted
amount of total protein.
To explain this reproducibility, we ranked all samples according
to their estimated protein expression levels after normalization
Figure 4. Prediction of protein expression: comparison between the models ModelSC1cs,2 cs,3 cs and 4cs. Summary of the three criteria
(CV criterion, regression criterion and correlation coefficient) of the four ModelSC1cs,2 cs,3 cs and 4cs, for the five anti-chk2 arrays. The ModelSC1cs is
used as a reference and set at 0. The differences to this reference are computed for the other ModelSC. The regression criterion cannot be calculated
for the ModelSC4cs, since this model includes a random effect.
doi:10.1371/journal.pone.0038686.g004
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then performed to compare the ranking of their estimated protein
expression levels. The obtained p-values, close to 1, show that
ranks of expression levels are conserved, no matter the used set of
ctrl and sypro arrays. In conclusion, despite a strong inter-array
variability, all ctrl and sypro arrays can be used for normalization
without affecting reproducibility of the data.
Required Number of Replicates
Next, we address how many replicates are required per sample
to evidence a given difference in expression level between two
samples. For this, we first need to estimate the variability of the
relative expression levels among replicates. Indeed, a higher
variability among replicates means that more replicates will be
required to significantly evidence a given difference in expression
level. Using the linear model in Equation 9 (see Materials and
Methods), we observe a significant inter-array variability, even on
the normalized data. Figure 5 represents the power curves for
increasing numbers of replicates (n from 2 to 5) as a function of the
difference in expression level (x-axis) varying from 2 to 15. The
plot confirms that the higher the number of replicates, the faster
the power grows, i.e the smaller the difference in expression needs
to be. Moreover, not much power is gained between 3 to 5
replicates, meaning that convergence is close to be reached. In
conclusion, with the variability observed in our experience, 3
replicates seems to be a good compromise between statistical
power and space optimization on the arrays.
Required Number of Serial Dilutions
In our experiment, 15 serial dilutions were printed for each
sample, allowing robust curve fitting and thus optimal estimation
Table 3. ModelSC 1: Capacity of the different models to
normalize for the varying amounts of total protein spotted.
Array Sample pval Ø Pvals pvalc pvalcs
1 BSA 3.5969e-05 0.1449 0.0420 0.3053
2 BSA 8.2330e-06 0.0991 0.0802 0.2175
3 BSA 1.5165e-06 0.5173 0.0003 0.0063
4 BSA 3.9442e-04 0.3741 0.0016 0.2308
5 BSA 8.2330e-06 0.0991 0.0802 0.2175
1 3T3 3.3674e-08 0.0710 0.0616 0.0644
2 3T3 1.0865e-06 0.2752 0.0561 0.0536
3 3T3 2.1981e-07 0.1603 0.6549 0.2578
4 3T3 1.6289e-10 0.2555 0.1080 0.2672
5 3T3 1.0865e-06 0.2752 0.0561 0.0536
Represented are the p-values of the amount effects without neither ctrl nor
sypro (pval1), with ctrl (pvalc), with sypro (pvals), with ctrl and sypro (pvalcs).
doi:10.1371/journal.pone.0038686.t003
Figure 5. Power curves. Power curves showing the difference in relative protein expression that can be evidenced with 2, 3, 4 or 5 technical
replicates.
doi:10.1371/journal.pone.0038686.g005
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show intensities at background levels and may thus not be essential
for the curve fitting. In addition, when many samples need to be
analyzed on the same array, the number of serial dilutions needs to
be reduced due to space limitation. Therefore, we studied how
many serial dilutions are required for robust estimation of
expression. For this, we took into account only the 2, 3, 5, 6 or
14 less diluted (most concentrated) dilution steps of each sample
and compared this to all 15 dilutions. Relative expression levels
were estimated with these varying numbers of dilutions. We then
compared estimated expression levels with true protein concen-
trations for the two most concentrated dilutions steps, which were
Figure 6. Protein expression prediction when using 2, 3, 5, 6, 14 or 15 serial dilutions for each sample. Summary of the three evaluation
criteria (CV criterion, regression criterion and correlation coefficient) for the five anti-chk2 arrays. The model using 2 dilutions is used as a reference
and set at 0. The differences to this reference are computed for the other number of dilutions. p-values (Anova test) are indicated.
doi:10.1371/journal.pone.0038686.g006
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computed the regression criterion and the correlation coefficient as
in Figure 3 while for the cross-validation criterion, only the two
common points were considered. We observe that all three criteria
significantly improve when the number of dilutions increases.
Moreover, a distinct improvement occurs between 3 and 5
dilutions, notably for the correlation coefficient and the regression
criterion. We therefore conclude that 5 serial dilutions per sample
is a good compromise between robust estimation of expression
levels and space optimization on the arrays.
Discussion
In this article, we propose a method to simultaneously quantify
and normalize RPPA data, based on the initial quantification
algorithm SuperCurve [15]. We show that the best normalization
model, which we call NormaCurve, takes into account the two
control arrays ctrl and sypro, as well as the two spatial effects Row
and Col. This model, validated by cross-validation, allows the
correction of spatial effects and corrects for differences in total
amount of spotted proteins. When we compared NormaCurve
with the initial SuperCurve model, significantly better correlations
with the true concentrations were obtained with NormaCurve.
Notably, we addressed the crucial issue of varying protein
amounts. We show that, in contrast to the initial SuperCurve
model, NormaCurve is able to correct for the total amount of
spotted protein when this latter varies between 1.2 and 0.8 mg/ml
for the first dilution step. Within this range, involuntary variation
in the concentration of a sample will thus be corrected by
NormaCurve and will not bias obtained results. A next step will be
to study up to which variability in the deposited amounts of
protein the normalization is satisfactory.
Interestingly, to correct for the total amount of spotted protein,
taking into account the two control arrays (both ctrl and sypro) is
not always better than taking either ctrl or sypro (Table 3). This
suggests that these two slides partially vehicle the same informa-
tion. Indeed, we observed that the background fluorescence
measured on the ctrl slide correlates with the total amount of
spotted protein. However, the ctrl array has an antibody-based
detection, similar to the protein detection protocol, while the sypro
array is a chemical staining procedure. The two slides are
therefore not expected to be entirely overlapping. Indeed, we
observe that inclusion of both ctrl and sypro arrays in our model
estimates relative protein expression levels that better reflect true
protein concentrations, compared to either ctrl or sypro alone
(Figure 3). Thus, ctrl and sypro arrays are complementary and
should both be included for an optimal normalization of the data.
The advantage of Normacurve, compared to microenvironment
normalization [21], is that control lysates are not required for
normalization. Thus, the entire array could be used for samples of
interest. NormaCurve is also attractive compared to median-based
normalization, in which the median of all arrays is simply set to the
same level for each sample. Indeed, in contrast to median-based
normalization, NormaCurve does not require a minimum amount
of antibodies to be powerful and it is not affected by a bias in the
chosen antibodies. Thus, NormaCurve appears as the most
versatile and useful normalization method currently available for
RPPA data.
In our experiment, we observed a significant difference among
replicate arrays, thus confirming the high inter-array variability
described elsewhere [20]. This implies that, when an important
number of samples are to be analyzed, these might better not be
divided over several arrays. Rather, a decreased number of
technical replicates and/or of dilution steps should be used for
each sample. Diminishing the number of serial dilutions impairs
the reliability of the estimated expression levels (Figure 6), while
diminishing the number of technical replicates affects the power in
the subsequent statistical analysis (Figure 5). We show that the
optimal compromise between data robustness and space optimi-
zation on the arrays consists of printing each sample in 5 serial
dilutions and 3 technical replicates.
All dilution steps, replicates and samples should be distributed as
randomly as possible over the array. This will make it possible to
optimize the normalization of potential spatial bias and ensure an
efficient identification of the relevant biological differences
between the samples under investigation.
In RPPA, spatial bias is mainly due to intrinsic heterogeneity of
nitrocellulose on the slides and to heterogeneous staining.
NormaCurve proposes a spatial normalization via two linear
covariates (Row and Col). Such spatial bias is a recurrent
problem in the microarray field and different methods have been
proposed to correct this artifact [24,25]. The MANOR method
initially developed for array-CGH experiment [24] did not
perform better than the proposed model (not shown). This may
be explained by the number of spots on RPPA arrays, which is
too low to efficiently estimate a spatial trend. However, future
technical improvements, such as diminished spot size through the
use of smaller spotting pins, might allow increasing the density of
spots on the arrays. Spatial normalization method would then
deserve to be re-evaluated.
Supporting Information
Figure S1 For a Chk2-labeled array, mean intensities were
plotted against the Coefficient of Variation for all samples and all
dilution steps. Note that high CVs are associated with low
intensities.
(TIF)
Figure S2 CV criterion, regression criterion and correlation
coefficient of the ModelSC 1 for the five arrays stained with anti-
Chk2.
(TIF)
Figure S3 Comparison of the ModelSC1cs,2 cs,3 cs and 4cs for
the five arrays stained with anti-Chk2.
(TIF)
Figure S4 Observed intensities on a Sypro Ruby stained array
for the dilution series of the BSA+chk2 samples with five different
starting concentrations (0.8, 0.9, 1, 1.1 and 1.2 mg/ml). The sypro
array correctly distinguishes between the different starting
concentrations.
(TIF)
Figure S5 Observed intensities on a control array (no primary
antibody) for the dilution series of the BSA+chk2 samples with five
different starting concentrations (0.8, 0.9, 1, 1.1 and 1.2 mg/ml).
The ctrl array distinguishes between the different starting
concentrations.
(TIF)
Methods S1 Reproductibility of control arrays.
(PDF)
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